Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:18:07 2024-05-15 EDT			5-day change	1st Jan Change
6.32 ^USD	+2.10%		-2.47%	+47.66%

05-09	Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company

October 20, 2023 at 05:26 pm

Lantern Pharma Inc. deeply regrets to announce the death of Dr. Franklyn Prendergast, a director of the Company. The Company learned on October 17, 2023 that Dr. Prendergast had died unexpectedly. Dr. Prendergast had served as a director of the Company since October 2019.

Latest news about Lantern Pharma Inc.

Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration	05-06	MT
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications	05-06	CI
Transcript : Lantern Pharma Inc. - Special Call	04-24
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion	04-22	MT
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan	04-22	CI
Transcript : Lantern Pharma Inc., Q4 2023 Earnings Call, Mar 18, 2024	03-18
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284	03-15	CI
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR	03-04	CI
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers	02-15	CI
Transcript : Lantern Pharma Inc., Q3 2023 Earnings Call, Nov 08, 2023	11-08
Lantern Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company	23-10-20	CI
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma	23-10-03	CI
Lantern Pharma Doses First Patient in Phase 1 Trial of Advanced Solid Tumor Drug Candidate	23-09-25	MT
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors	23-09-25	CI
Sector Update: Health Care Stocks Mixed Monday Afternoon	23-09-18	MT
FDA Clears Lantern Pharma's Investigation New-Drug Application for LP-284	23-09-18	MT
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin?s Lymphomas	23-09-18	CI
Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting	23-08-31	CI
Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors	23-08-28	CI
Lantern Pharma Receives US Patent Allowance Notice for LP-184 to Treat Rare Pediatric Brain Cancer	23-08-14	MT
Lantern Pharma Inc. Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT	23-08-14	CI

Chart Lantern Pharma Inc.

Duration

Period

More charts

Company Profile

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Investor Meeting - Key Opinion Leaders

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.19 USD

Average target price

22 USD

Spread / Average Target

+255.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LANTERN PHARMA INC.	+47.66%	66.6M
MODERNA, INC.	+27.42%	49.18B
IQVIA HOLDINGS INC.	+0.65%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.55%	18.71B
BIO-TECHNE CORPORATION	+7.91%	13.26B
MEDPACE HOLDINGS, INC.	+32.24%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.14%	11.99B

Other Biotechnology & Medical Research